|Home | About | Journals | Submit | Contact Us | Français|
In the accompanying study, we show how retroviral tropism can be redirected by insertion of short peptide ligands at multiple locations in envelope. Here we use this approach to selectively target and destroy human cancer cells. Many cancer cells overexpress specific cell surface receptors. We have generated Moloney murine leukemia virus (MLV) envelope derivatives bearing short peptide ligands for gastrin-releasing protein (GRP) and human epidermal growth factor receptors. Pseudotyped viruses containing these chimeric envelope derivatives selectively transduce human cancer cell lines that overexpress the cognate receptor. A retrovirus targeting the GRP receptor can deliver the thymidine kinase gene to human melanoma and breast cancer cells, which are killed by the subsequent addition of ganciclovir. Collectively, our results demonstrate that short peptide ligands inserted at appropriate locations in MLV envelope can selectively target retroviruses to human cancer cells and deliver a therapeutically relevant gene.
Retroviral vectors have been used extensively in gene therapy experiments and clinical trials. In the accompanying article (12), we have described a method to alter the tropism of Moloney murine leukemia virus (MLV) ecotropic envelope to target specific receptors on human cells. Gastrin-releasing protein (GRP) is an autocrine and paracrine growth factor (19) belonging to the bombesin family of peptides. The 14-amino-acid bombesin peptide is homologous to the C terminus of GRP and binds with high affinity to the GRP receptor, a member of the G-protein-coupled receptor family (28). The GRP receptor is overexpressed in a variety of carcinomas (11, 18, 20, 25, 27, 31) and is therefore an attractive target for gene therapy.
The epidermal growth factor receptor (EGFR) family consists of at least four members: EGFR (HER1, erbB-1), HER2 (erbB-2), HER3 (erbB-3), and HER4 (erbB-4). Specific members of the epidermal growth factor receptor family are also overexpressed in certain human adenocarcinomas, including breast and ovarian cancers. Overexpression of at least two family members, EGFR and HER2, is associated with poor prognosis and differential response to therapy (15, 16). Heregulin protein (HRG) is a growth factor that has several homologous isoforms that bind directly to HER3 (erbB-3) and HER4 (erbB-4) homodimers and heterodimers containing the HER2 receptor (10, 23, 29). In previous studies, pseudotyped virus has been directed to HER2, HER3, and HER4, by single-chain variable fragments or the HRG protein appended to the N terminus of envelope (8, 13, 26).
Using the method outlined in the accompanying study (12), we examine more than 20 MLV chimeric envelope derivatives that contain the GRP or a modified HRG peptide ligand inserted at various locations within envelope. We demonstrate that this approach can be used to selectively target cancer cells overexpressing GRP or HRG receptors and deliver a therapeutically relevant gene.
The 21-amino-acid GRP sequence, containing 14 residues of the bombesin protein, was inserted at various locations within the MLV ecotropic envelope to generate 14 GRP chimeric envelope derivatives (Table (Table1).1). Pseudotyped virus producer cells were generated for each chimeric envelope derivative, and the resultant GRP viruses initially tested for transduction of host NIH 3T3 cells. Figure Figure11 shows that all of the GRP viruses transduced NIH 3T3 cells, except when the ligand was inserted within the N-terminal region (GRP-2 and GRP-3) or in one case within the VRA (GRP-5). In general, the GRP viruses transduced NIH 3T3 cells with efficiencies comparable to that observed in the accompanying study (12).
A375 human melanoma and 231 breast carcinoma cells overexpress the GRP receptor (17, 21, 33). GRP viruses with insertions at the N terminus (GRP-1), within the N-terminal region (GRP-2 and GRP-3), within the VRA (GRP-4 and GRP-5), downstream of the VRB (GRP-8), and upstream of the PRR (GRP-9) transduced both human cell lines. In contrast, GRP viruses with insertions within the PRR (GRP-10) or C-terminal region (GRP-11 to GRP-14) failed to transduce human cells.
We next performed experiments to confirm that expression of the GRP receptor is required for GRP viruses to transduce human cells. First, we tested whether treatment of GRP viruses with an antibody to the GRP protein would block transduction of human cells. Figure Figure2A2A shows that 2A11, an antibody to the C-terminal region of GRP protein, substantially reduced transduction of both human cancer cell lines but not mouse NIH 3T3 cells. Thus, GRP is required for transduction of human cells but not mouse cells.
Second, we sought to determine whether expression of the GRP receptor was required for transduction of human cells by GRP viruses. Human 293 cells do not express the GRP receptor (30). We derived a 293 cell line that constitutively expresses the GRP receptor (293-GRPR cells). Figure Figure2B2B shows that 293-GRPR cells, but not the parental 293 cells, were transduced by GRP viruses and that pretreatment with the 2A11 antibody blocked transduction. In a related experiment, Fig. Fig.2C2C shows that several of the GRP viruses transduced mouse Swiss 3T3 cells, which express the GRP receptor, but not NIH 3T3 cells, which lack the GRP receptor. Collectively, the results of Fig. Fig.22 indicate that transduction of human cells by GRP viruses requires a virus bearing a chimeric GRP envelope derivative and a cell expressing a GRP receptor.
We also constructed a series of chimeric envelope derivatives containing the 56 amino acid heregulin-β peptide sequence (Table (Table1).1). A region encompassing residues 177 to 226 of HRG binds to and activates the HER3 and HER4 receptors and was selected as the target ligand (3). This ligand was modified through 11 substitutions known to increase its affinity for the homodimeric HER3 (2) (Table (Table1).1). The HRG ligand was inserted in locations that had enabled transduction of human cells by GRP (Fig. (Fig.1)1) and RGD viruses (12).
HRG viruses were first tested for their ability to transduce NIH 3T3 cells. Figure Figure3A3A shows that transduction efficiencies of the HRG-8 and HRG-9 viruses were comparable to the equivalent GRP viruses (GRP-9 and GRP-10; Fig. Fig.1).1). In contrast, the transduction efficiencies of the HRG-1, HRG-4, HRG-6, and HRG-7 viruses were significantly lower than the equivalent GRP viruses (GRP-1, GRP-4, GRP-6, and GRP-8).
MDA-MB-453 breast carcinoma cells overexpress EGFR family members, whereas MDA-MB-231 breast carcinoma cells do not (5, 6, 14). Figure Figure3A3A shows that the HRG-1 and HRG-8 viruses transduced MDA-MB-453 cells but not MDA-MB-231 cells. The HRG-1 and HRG-8 viruses also transduced two other human breast cancer cell lines that overexpress EGFR family members: MCF-7 and AU-565 cells (data not shown). In contrast, HRG-2, HRG-3, HRG-4, HRG-5, and HRG-7 failed to transduce MDA-MB-453 cells, which was unexpected based upon the results with the equivalent GRP viruses. Pretreatment of MDA-MB-453 cells with HER3 and HER4 antibodies substantially decreased transduction by HRG-1 and HRG-8 viruses, indicating that viral entry was mediated by the HRG-receptor interaction (Fig. (Fig.3B3B).
Finally, we tested whether retroviruses bearing an appropriate chimeric envelope derivative could deliver a therapeutically relevant gene to cancer cells. Mammalian cells expressing the herpes simplex virus thymidine kinase (TK) gene are killed by treatment with ganciclovir (7). The GRP-1 virus carrying the herpes simplex virus TK gene was used to transduce A375 human melanoma and MDA-MB-231 breast carcinoma cells. After ganciclovir treatment of transduced melanoma and breast carcinoma cells significant cell death was evident, whereas there was no cytopathic effect in ganciclovir-treated cells transduced by a control GRP-1 virus not expressing the TK gene (Fig. (Fig.44).
This study demonstrates that small ligands inserted into the ecotropic MLV envelope can alter the tropism of pseudotyped virus to target specific receptors on human cancer cells. These results confirm other studies from our laboratory (12) and highlight the importance of the effect of ligand length and position within the envelope on transduction efficiency and tropism. For both GRP and HRG viruses, some insertions within the N-terminal region or VRA interfered with the transduction of mouse cells. Several of these GRP viruses transduced cells expressing the GRP receptor, indicating that tropism had been switched. Thus, for the production of selective targeting retroviral vectors, the N-terminal region and VRA may be the optimal locations for ligand insertion.
Transduction by viruses containing the larger HRG ligand was, in general, decreased relative to their GRP counterparts, and several HRG viruses were unable to transduce mouse or human cells. The HRG ligand is twice the length of the GRP ligand and may have a more disruptive effect on envelope structure and function. It has been reported that certain modified envelope proteins cannot undergo the postbinding conformational change required for transduction (34), and some of the chimeric HRG envelope derivatives may be examples of this phenomenon. The decreased transduction efficiency of HRG viruses may also be related to the HER3 and HER4 receptors that they target. For example, receptors have different rates of internalization into endosomes, and the virus must be in close proximity to the endosomal membrane for fusion to occur. The HER2 receptor is not rapidly endocytosed (4, 24), which may explain the lower transduction efficiency of HRG viruses.
Transduction efficiency also depends on the presentation of the ligand within the envelope. In this and in the accompanying study, cysteine residues flanked the insert and are expected to form a disulfide bond that facilitates ligand presentation. Screening for receptor binding peptides within a constrained disulfide loop structure by using phage display or recombinant peptide libraries (1, 9, 22, 32) in conjunction with the method described here may provide a general approach for targeting retroviral vectors to specific cells.
We thank S. Jones and J. F. Battey for plasmids, F. Cuttitta for the 2A11 antibody, and W. S. Pear for Anjou 65 cells.
This work was supported in part by an NIH grant to M.R.G. M.R.G. is an investigator of the Howard Hughes Medical Institute.